Active, not recruitingPhase 3NCT03480360
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
Studying Acute panmyelosis with myelofibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Dartmouth-Hitchcock Medical Center
- Principal Investigator
- Kenneth Meehan, MDDartmouth-Hitchcock Medical Center
- Intervention
- Cyclophosphamide(drug)
- Enrollment
- 21 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2018 – 2026
Study locations (1)
- Dartmouth Hitchcock Medical Center, Norris Cotton Cancer Center, Lebanon, New Hampshire, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03480360 on ClinicalTrials.govOther trials for Acute panmyelosis with myelofibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGEARLY PHASE1NCT06398457Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific AntibodiesSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- RECRUITINGNANCT05875805A Telehealth Advance Care Planning InterventionUniversity of Rochester
- ACTIVE NOT RECRUITINGPHASE1NCT05455294Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid NeoplasmsJacqueline Garcia, MD
- RECRUITINGPHASE1NCT04771572Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.Newave Pharmaceutical Inc
- ACTIVE NOT RECRUITINGPHASE2NCT04060277Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell TransplantationCity of Hope Medical Center